New York Medical College

Clinical research site in Valhalla, New York · 15 DANA ROAD, BASIC SCIENCES BLDG ROOM C21, VALHALLA, NY 10595-1646 · (914) 594-4730

Part of New York Medical College

As of July 2026, 42 paid clinical trials are recruiting at New York Medical College in Valhalla, New York. Active studies at this site cover conditions such as Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at New York Medical College (42)

Pompe Disease Registry Protocol

for Glycogen Storage Disease Type II

74 locations incl. Birmingham

Sponsor: Genzyme, a Sanofi Company

Sex: All·Age: All ages

Code: NCT00231400·Recruiting·Listed Oct 2005

Apply to this trial

Fabry Disease Registry & Pregnancy Sub-registry

for Fabry Disease

74 locations incl. Birmingham

Sponsor: Genzyme, a Sanofi Company

Sex: All·Age: All ages

Code: NCT00196742·Recruiting·Listed Sep 2005

Apply to this trial

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

for DLBCL

23 locations incl. Glendale

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT05139017·Phase 2, Phase 3·Recruiting·Listed Dec 2021

Apply to this trial

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

for Gaucher Disease

70 locations incl. Phoenix

Sponsor: Genzyme, a Sanofi Company

Sex: All·Age: All ages

Code: NCT00358943·Recruiting·Listed Aug 2006

Apply to this trial

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

for Malignant Neoplasm

17 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 1 Month - 17

Code: NCT06941272·Phase 1, Phase 2·Recruiting·Listed Apr 2025

Apply to this trial

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

for B-cell Acute Lymphoblastic Leukemia

17 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 6 Months - 25

Code: NCT06395103·Phase 1, Phase 2·Recruiting·Listed May 2024

Apply to this trial

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

for Juvenile Idiopathic Arthritis

10 locations incl. Phoenix

Sponsor: AbbVie

Sex: All·Age: 1 - 17

Code: NCT05609630·Phase 3·Recruiting·Listed Nov 2022

Apply to this trial

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

for Cystic Fibrosis

13 locations incl. Birmingham

Sponsor: ReCode Therapeutics

Sex: All·Age: 18 - 60·Accepts healthy volunteers

Code: NCT06237335·Phase 2·Recruiting·Listed Feb 2024

Apply to this trial

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

for Malignant Neoplasm

7 locations incl. Iowa City

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 1 Month - 17

Code: NCT07630974·Phase 1, Phase 2·Recruiting·Listed Jun 5, 2026

Apply to this trial

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

for Acute Myeloid Leukemia

3 locations incl. Palo Alto

Sponsor: AbbVie

Sex: All·Age: 6 Months - 17

Code: NCT07306832·Phase 1·Recruiting·Listed Dec 2025

Apply to this trial

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

for B-cell Acute Lymphoblastic Leukemia

9 locations incl. Duarte

Sponsor: Vironexis Biotherapeutics Inc.

Sex: All·Age: 13 - 90

Code: NCT06533579·Phase 1, Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

for Childhood Extracranial Germ Cell Tumor

387 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT03067181·Phase 3·Recruiting·Listed Mar 2017

Apply to this trial

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

for High Grade Osteosarcoma

177 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 40

Code: NCT05691478·Phase 2, Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for B Acute Lymphoblastic Leukemia

188 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 25

Code: NCT03959085·Phase 3·Recruiting·Listed May 2019

Apply to this trial

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

for B Acute Lymphoblastic Leukemia

141 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 366 Days - 46

Code: NCT06124157·Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for Acute Myeloid Leukemia

171 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT04293562·Phase 3·Recruiting·Listed Mar 2020

Apply to this trial

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

for Recurrent Langerhans Cell Histiocytosis

103 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 180 Days - 22

Code: NCT05828069·Phase 2·Recruiting·Listed Apr 2023

Apply to this trial

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

for Acute Lymphoblastic Leukemia

156 locations incl. Birmingham

Sponsor: PedAL BCU, LLC

Sex: All·Age: Up to 22

Code: NCT04726241·Phase 1, Phase 2·Recruiting·Listed Jan 2021

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

153 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting·Listed Dec 2023

Apply to this trial

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

for Low Grade Astrocytoma

117 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 2 - 21

Code: NCT04166409·Phase 3·Recruiting·Listed Nov 2019

Apply to this trial

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

for Childhood Medulloblastoma

101 locations incl. Mobile

Sponsor: Children's Oncology Group

Sex: All·Age: 4 - 21

Code: NCT05382338·Phase 3·Recruiting·Listed May 2022

Apply to this trial

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

for Acute Leukemia of Ambiguous Lineage

112 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 365 Days

Code: NCT06317662·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Project: Every Child for Younger Patients With Cancer

for Adrenal Gland Pheochromocytoma

233 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 25

Code: NCT02402244·Recruiting·Listed Mar 2015

Apply to this trial

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

for Anaplastic Kidney Wilms Tumor

171 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 30

Code: NCT04322318·Phase 2·Recruiting·Listed Mar 2020

Apply to this trial

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

for Metastatic Malignant Neoplasm in the Lung

211 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 50

Code: NCT05235165·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

for Stage I Mixed Cell Type Kidney Wilms Tumor

146 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 30

Code: NCT06401330·Phase 3·Recruiting·Listed May 2024

Apply to this trial

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

for Central Nervous System Nongerminomatous Germ Cell Tumor

134 locations incl. Anchorage

Sponsor: Children's Oncology Group

Sex: All·Age: 3 - 29

Code: NCT04684368·Phase 2·Recruiting·Listed Dec 2020

Apply to this trial

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

for Anaplastic Large Cell Lymphoma, ALK-Positive

1 location in Valhalla

Sponsor: New York Medical College

Sex: All·Age: 1 - 39

Code: NCT07013565·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

for Pleuropulmonary Blastoma

76 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT06647953·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

for Embryonal Rhabdomyosarcoma

163 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT05304585·Phase 3·Recruiting·Listed Mar 2022

Apply to this trial

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

for Diffuse Midline Glioma, H3 K27-Altered

34 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 12 Months - 21

Code: NCT04870944·Phase 1, Phase 2·Recruiting·Listed May 2021

Apply to this trial

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

for Ewing Sarcoma

1 location in Valhalla

Sponsor: New York Medical College

Sex: All·Age: 1 - 30

Code: NCT04308330·Phase 1·Recruiting·Listed Mar 2020

Apply to this trial

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for Ganglioneuroblastoma

145 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 30

Code: NCT03126916·Phase 3·Recruiting·Listed Apr 2017

Apply to this trial

CMV CTLs in Neonates With CMV Infection

for Congenital Cytomegaloviral (CMV) Disease

4 locations incl. Los Angeles

Sponsor: New York Medical College

Sex: All·Age: 0 Days - 21 Days

Code: NCT05564598·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

for B-cell Lymphoma

1 location in Valhalla

Sponsor: New York Medical College

Sex: All·Age: 12 - 70

Code: NCT04491370·Phase 1, Phase 2·Recruiting·Listed Jul 2020

Apply to this trial

SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease

for Covid19

4 locations incl. Valhalla

Sponsor: New York Medical College

Sex: All·Age: 18 - 65

Code: NCT04896606·Phase 1, Phase 2·Recruiting·Listed May 2021

Apply to this trial

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

for Cytomegalovirus Infections

9 locations incl. Los Angeles

Sponsor: New York Medical College

Sex: All·Age: 1 Month - 79

Code: NCT03266640·Phase 2·Recruiting·Listed Aug 2017

Apply to this trial

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

for NK-Cell Lymphoma

6 locations incl. Birmingham

Sponsor: New York Medical College

Sex: All·Age: 1 - 31

Code: NCT03719105·EARLY_Phase 1·Recruiting·Listed Oct 2018

Apply to this trial

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

for Non-Hodgkin Lymphoma

1 location in Valhalla

Sponsor: New York Medical College

Sex: All·Age: 3 - 31

Code: NCT02393157·Phase 2·Recruiting·Listed Mar 2015

Apply to this trial

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

for Epstein-Barr Virus Infections

8 locations incl. Los Angeles

Sponsor: New York Medical College

Sex: All·Age: 1 Month - 79

Code: NCT03266653·Phase 2·Recruiting·Listed Aug 2017

Apply to this trial

Showing the 40 most relevant of 42 recruiting trials at this site. Browse all with filters →

More research sites in Valhalla

Westchester Medical Center (34 trials)
Maria Fareri Children's Hospital (4 trials)
New York Medical College at Westchester Medical Center (4 trials)
Gatorade Sports Science Institute (2 trials)
New York Medical Center (2 trials)
New York Medical Center/ Maria Fareri Children's Hospital (2 trials)
Anthos Investigative (1 trial)
Boston Childrens Health Physicians (1 trial)
GSSI Valhalla (1 trial)
Maria Fareri Children's Hospital (West Chester Medical) (1 trial)

Explore more

Paid clinical trials in Valhalla, NY · New York clinical trials